Insulin infusion sets worn for more than 4–5 days have been associated with a greater risk of
unexplained hyperglycemia, a phenomenon that has been hypothesized to be caused by an …

m-Cresol and methyl p-hydroxybenzoate are preservatives in insulin preparations. As
previously reported, in diabetic patients on continuous subcutaneous insulin infusion, users …

The approximation of euglycemia is the most effective means of preventing diabetic
complications, which is achieved through effective insulin delivery. Recent reports indicate …

Abstract Continuous Subcutaneous Insulin Infusion (CSII) is superior to conventional insulin
therapy as it improves glycemic control thus reducing the probability of diabetic …

Skin reactions at the infusion site are a common side effect of continuous subcutaneous
insulin infusion therapy. We hypothesized that local skin complications are caused by …

Background: Exogenous insulin therapy requires stabilization of the insulin molecule, which
is achieved through the use of excipients (eg, phenolic preservatives (PP)) that provide …

Objective This study investigated the effects of the inflammatory tissue response (ITR) to an
insulin infusion set (IIS) on insulin bolus spread over wear time, as well as the effect of …

Objective: Develop a test methodology for evaluating the reason for infusion set (IS) failure
in persons with diabetes using insulin pump therapy (Continuous Sub-cutaneous Insulin …

One major obstacle that limits the lifespan of insulin infusion pumps is surmounting the
tissue site reaction at the device implantation site. All commercial insulin formulations …

Background Extending the lifespan of subcutaneous insulin administration sets and infusion
pumps requires overcoming unreliable insulin delivery induced by dermal reactions. All …